鼠类肉瘤病毒癌基因状态对晚期肺腺癌患者近远期预后及化疗不良反应发生率的影响

Effects of kirsten rat sarcoma viral oncogene state on short-and long-term prognosis and incidence rate of adverse reactions caused by chemotherapy in patients with advanced lung adenocarcinoma

目的探讨鼠类肉瘤病毒癌基因(Kras)状态对晚期肺腺癌近远期疗效及化疗不良反应发生率的影响。方法选取晚期肺腺癌的患者88例,按照Kras基因状态分为突变型组20例和野生型组68例。比较两组患者在使用一线化疗方案后的近期疗效、不良反应发生率和无疾病进展生存期。结果两组患者的客观缓解率、疾病控制率及化疗不良反应发生率比较,差异均无统计学意义(均P>0.05)。野生型组的无疾病进展生存期长于突变型组(P<0.05)。结论 Kras基因状态对晚期肺腺癌患者化疗短期疗效和不良反应发生率均无影响,但Kras基因突变者远期预后较差。

Objective To investigate the effects of kirsten rat sarcoma viral oncogene（ Kras ）gene state on the short- and long-term efficacy and incidence rate of adverse reactions caused by chemotherapy in patients with advanced lung adenocarcinoma. Methods Eighty-eight patients with advanced lung adenocarcinoma were enrolled and were divided into mutation group（ n =20）and wild group（ n =68）according to the Kras gene state.The short-term efficacy,incidence rate of adverse reactions,and progression-free survival were compared between the two groups after first-line chemotherapy. Results There was no significant difference in the objective response rate,disease control rate or incidence rate of adverse reactions caused by chemotherapy between the two groups（all P 〉0.05）.The progression -free survival of the wild group was longer than that of the mutation group（ P 〈0.05）. Conclusion The state of Kras gene has few effects on the short-term efficacy caused by chemotherapy or the incidence rate of adverse reactions in patients with advanced lung adenocarcinoma ,but patients with Kras gene mutation had a poor long-term prognosis.